Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials...

-- Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT -- SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company...

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR)...

-- Company presentation scheduled for August 14, 2018 at 8:00 a.m. EDT -- SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company...

-- ZEMDRI (plazomicin), approved in the U.S. for the treatment of adults with complicated urinary tract infections -- -- Launch of ZEMDRI underway; reached more than three quarters of high priority...

--- Add-on Payment to Provide Additional Medicare Reimbursement up to 50% of the cost of ZEMDRI Prescribed to Medicare patients in Hospital Inpatient Setting --- SOUTH SAN FRANCISCO, Calif., Aug. ...

-- Restructuring to improve cost structure and focus corporate priorities to reduce overall capital needs -- -- Commercial and Medical Affairs teams unchanged by restructuring as the Company executes...

SOUTH SAN FRANCISCO, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address...

-- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro microbiological activity against pathogens designated by the CDC as urgent and serious public health threats,...

― Key opinion leaders Steven Burdette, M.D., (Professor of Medicine at Wright State University Boonshoft School of Medicine) and Joshua Rosenberg, M.D. (Chair of Critical Care at The Brooklyn Hospital...